Tag Archives: Ziopharm Oncology

H.C. Wainwright Reaffirms Their Hold Rating on Ziopharm Oncology (ZIOP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Ziopharm Oncology (ZIOP – Research Report). The company’s shares closed last Friday at $3.20. According to TipRanks.com, Ramakanth is a 5-star analyst with an average

What Made H.C. Wainwright Downgrade Ziopharm Oncology’s Stock?

In a report released today, Swayampakula Ramakanth from H.C. Wainwright downgraded Ziopharm Oncology (ZIOP – Research Report) to Hold. The company’s shares closed last Friday at $5.33, close to its 52-week high of $5.95. According to TipRanks.com, Ramakanth is a

Ziopharm Oncology (ZIOP) Receives a Buy from Raymond James

In a report issued on May 29, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report). The company’s shares closed last Thursday at $2.74. According to TipRanks.com, Novak is a 3-star analyst with

Cantor Fitzgerald Reiterates Overweight on Ziopharm Oncology Shares, Sees 83% Upside For The Stock

In a research report published on 5/29, Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Ziopharm Oncology (NASDAQ:ZIOP)with a price target of $6, which represents a potential upside of 83% from where the stock is currently trading. According

Laidlaw Reiterates Their Buy Rating on Ziopharm Oncology (ZIOP)

In a report issued on June 1, Yale Jen from Laidlaw reiterated a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP), with a price target of $7.50. The company’s shares closed last Friday at $3.27. Currently, the analyst consensus on Ziopharm

H.C. Wainwright Reiterates Their Buy Rating on Ziopharm Oncology (ZIOP)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Ziopharm Oncology (ZIOP – Research Report) today and set a price target of $6.50. The company’s shares closed last Monday at $2.90, close to its 52-week low of $2.68. According